Clinical Trial Update: A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis [Phase 1]

View source ↗

Summary

The Phase 1 trial of ELND002 in relapsing forms of multiple sclerosis sponsored by Elan Pharmaceuticals has been terminated. The document provides status inform…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ELND002

Snippet

Sponsor: Elan Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 1 | Status: TERMINATED